FDA Delays Decision On Merck & Co., Inc. Shingles Vaccine

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Feb. 24, 2006--The U.S. Food and Drug Administration (FDA) is extending the review period for the Biologics License Application (BLA) for ZOSTAVAX(R) (zoster vaccine live (Oka/Merck)), Merck's investigational shingles vaccine, to review additional information that Merck submitted during the review process. The FDA has informed Merck that the agency's new review goal date for the application for ZOSTAVAX is May 25.